Vaccines for immunoprevention of DNA mismatch repair deficient cancers.

ABSTRACT: The development of cancer vaccines to induce tumor-antigen specific immune responses was sparked by the identification of antigens specific to or overexpressed in cancer cells. However, weak immunogenicity and the mutational heterogeneity in many cancers have dampened cancer vaccine successes. With increasing information about mutational landscapes of cancers, mutational neoantigens can be predicted computationally to elicit strong immune responses by CD8 +cytotoxic T cells as major mediators of anticancer immune response. Neoantigens are potentially more robust immunogens and have revived interest in cancer vaccines. Cancers with deficiency in DNA mismatch repair have an exceptionally high mutational burden, including predictable neoantigens. Lynch syndrome is the most common inherited ca

SUBMITTER: Hernandez-Sanchez A 

PROVIDER: S-EPMC9226910 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature